Leading Australian pharmaceutical group Phebra, is pleased to announce a further expansion of its Sydney multi-purpose sterile injectables plant, unveiling a new aseptic laboratory and packaging warehouse which will double capacity and help secure the supply of critical medicines to local and overseas markets.
Phebra CEO, Andre Vlok said the second stage of expansion across Phebra’s multi-purpose sterile injectables plant at Lane Cove West generates increased filling and packing capacities. Phebra’s Therapeutic Goods Administration (TGA) manufacturing licence has
been amended to include its new robotic aseptic syringe and vial line.
“The expansion follows the installation of our new aseptic processing systems and will significantly increase Phebra’s warehousing and packaging hall. It has strengthened our capability to widen our primary container type offerings (vials and syringes), increase batch sizes and boost our capacity to supply greater quantities of our products to local and overseas markets,” Mr Vlok, said today.
“Our ongoing manufacturing expansion program has been focused on the introduction of state-of-the-art robotic manufacturing capability which has enhanced the reputation of Phebra as a globally compliant manufacturer.”
“The strategy also improves Phebra’s ability to build-on the resilience of Australia’s pharmaceutical supply chain. With more components being locally manufactured, we can safeguard the supply of our portfolio of critical medicines, whilst reducing the risks
associated with recent COVID disruptions to the global supply chain.”
Mr Vlok said the additional floor-space for visual inspections, labelling, packaging warehousing and support services, will ensure Phebra controls the production and supply of many of its products listed on the COVID-19 TGA Essential Medicines List.